- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03562845
Evaluation of Immunobiogram® as a Tool in Adjustment of Immunosuppressant Therapy for Renal Transplant (TRANSBIO)
Evaluation of the Clinical Consistency and Analytical Robustness of Immunobiogram® as an In Vitro Diagnostics Biotechnological Tool to Help Decision-making in Adjustment of Immunosuppressant Therapy for Renal Transplant
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Alberto Vazquez
- Phone Number: +34 912 187 043
- Email: alberto.vazquez@biohope.eu
Study Contact Backup
- Name: Karen Konisky
- Phone Number: 978-807-2525
- Email: kkonisky@comcast.net
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 25 years and < 70 years.
- Male and Female.
- Renal transplant performed at least 1 year before inclusion.
ARM 1:
Bad clinical evolution: patients with renal dysfunction and positive biopsy to rejection OR significant increase in strength of DSA expressed as Luminex MFI. Specifically, the following two criteria must comply:
- Renal function progressive deterioration, with significant creatinine increase of at least 15% for 18 months and/or proteinuria over > 500 mg/day or ratio protein/creatinine> 500 mg/g DE NOVO or increase in 50%.
- Biopsy in the last 12 months that shows positive signs attributable to any kind of immunological response compatible with any type of rejection AND/OR at least 50% increase in strength of DSA expressed as Luminex MFI in comparison with previous determination and always at titers more than 3000UI.
Good clinical evolution: patients without rejection episodes, negative DSA, stable renal function and no changes in treatment in the past 12 months. ALL the following criteria must apply
- Stable renal function in the past 12 months
- NO DSA titers
- No history of previous rejection episodes
- Stable immunosuppressive medication (No change in prednisone or MPA dose and tacrolimus dose with changes <20% of the dose) in the past 12 months
ARM 2:
- Stable renal function
- No DSA titers
- No history of previous rejection episodes
- Stable immunosuppressive medication (No change in prednisone or MPA dose and tacrolimus dose with changes <20% of the dose) at least in the past 18 months
Exclusion Criteria:
- Rejection of informed consent
- Active systemic infections that needed antimicrobial treatment in the past two months
- Active immune-based diseases with acute outbreaks in the past 12 months, despite immunosuppressive treatment
- Severe ischemia-reperfusion injury of current renal transplant with delayed graft function objectively evident at more than 20 days after transplant AND/OR kidney transplanted from a deceased, very elderly donor (>80 years)
- Double transplant (renal + another organ)
- HIV, HBV, HCV infection or other severe infectious diseases that prevent blood samples from being processed in a conventional laboratory
- Chronic Allograft Injury (CAI) unlikely related to immune processes, by the Investigator´s judgement
- Recurrent primary kidney disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ARM 1-Bad vs Good Clinical Evolution
This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:
IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences. |
NA-Observational only
|
ARM 2-Stable Renal Transplant Patients
This arm is intended to evaluate robustness of Immunobiogram® as an IVD test.
Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days).
The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
|
NA-Observational only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the robustness of Immunobiogram® (IMBG) as an in vitro Diagnostic Bioassay to study the sensitivity/resistance patterns of Immunosuppressant drugs in Renal Transplantation
Time Frame: Baseline and 30 days
|
Robustness of Immunobiogram® (IMBG) as an In Vitro Diagnostic Bioassay to study the sensitivity/resistance patterns of Immunosuppressant drugs in Renal Transplantation, evaluated as follows:
|
Baseline and 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate intrasubject and inter-time consistency of Immunobiogram®
Time Frame: Baseline and 30 days
|
Immunobiogram® shows intrasubject and inter-time consistency in terms of similarity with a maximum +/- 30% variation ID50, in the average response of the three IMBG performed on inclusion and the average response of the three IMBG performed one month after inclusion, provided that no significant clinical or immunological events happened during follow-up, as assessed with a specifically provided questionnaire and the Investigator´s judgement
|
Baseline and 30 days
|
Evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical evolution
Time Frame: Baseline
|
ARM 1 describes the Immunobiogram® discrimination ranges based on the correlation with the results of sensitivity/resistance patterns to immunosuppressants as regards the trend of clinical progression in each patient.
|
Baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Julio Pascual, MD, PhD, Parc du Salut Mar
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- BHP-IBG-2017-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on NA-Observational only
-
University College, LondonActive, not recruiting
-
University of ManitobaUnknown
-
Wageningen UniversityNexira; Roquette Freres; Netherlands: Ministry of Health, Welfare and Sports; B... and other collaboratorsCompletedIrritable Bowel Syndrome | Microbial Colonization | Dietary HabitsNetherlands
-
National Taiwan University HospitalNational Taiwan University Hospital Hsin-Chu Branch; National Taiwan University...RecruitingHeart Failure With Preserved Ejection Fraction | Amyloidosis CardiacTaiwan
-
NoNO Inc.University of CalgaryCompletedStroke, AcuteUnited States, Ireland, Korea, Republic of, Canada, Sweden, Germany, United Kingdom, Australia
-
University of Colorado, BoulderEmory University; Sonoma Technology, Inc.RecruitingBreast Feeding | Environmental Exposure | Infant DevelopmentUnited States
-
University of British ColumbiaRecruiting
-
Henan Provincial People's HospitalNot yet recruiting
-
University of VirginiaRecruiting
-
Christine HenriRecruitingHeart Failure | Aortic StenosisCanada